---
title: "Prostate Cancer Clinical Trials in California"
description: "Find 1,210 clinical trials for prostate cancer near California. Connect with research centers in your area."
url: "https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/california"
---

# Prostate Cancer Clinical Trials in California

Find 1,210 clinical trials for prostate cancer near California. Connect with research centers in your area.

- [All Prostate Cancer trials nationwide](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer)
- [All trials in California](https://www.clareohealth.com/clinical-trials/location/california)

Showing 1-20 of 1,210 trials

### [Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue](https://www.clareohealth.com/clinical-trials/NCT04972097)

Status: COMPLETED · Phase: NA · NCT04972097 · Orange, California and 16 others · Sponsor: Angiodynamics, Inc.

Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients.

### [Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy](https://www.clareohealth.com/clinical-trials/NCT00005810)

Status: COMPLETED · Phase: PHASE2 · NCT00005810 · San Francisco, California and 6 others · Sponsor: Alliance for Clinical Trials in Oncology

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

### [A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations](https://www.clareohealth.com/clinical-trials/NCT07038369)

Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · NCT07038369 · Los Angeles, California and 7 others · Sponsor: Atavistik Bio, Inc

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/H…

### [Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC](https://www.clareohealth.com/clinical-trials/NCT04060394)

Status: COMPLETED · Phase: PHASE1/PHASE2 · NCT04060394 · Tucson, Arizona and 16 others · Sponsor: Laekna Limited

The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic cast…

### [AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)](https://www.clareohealth.com/clinical-trials/NCT07285694)

Status: TERMINATED · Phase: PHASE1/PHASE2 · NCT07285694 · Duarte, California and 8 others · Sponsor: Arsenal Biosciences, Inc.

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

### [A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer](https://www.clareohealth.com/clinical-trials/NCT06395753)

Status: COMPLETED · Phase: PHASE2 · NCT06395753 · Mesa, Arizona and 20 others · Sponsor: Debiopharm International SA

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

### [A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC](https://www.clareohealth.com/clinical-trials/NCT07226986)

Status: RECRUITING · Phase: PHASE1/PHASE2 · NCT07226986 · Los Angeles, California and 24 others · Sponsor: Novartis Pharmaceuticals

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) v…

### [Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients](https://www.clareohealth.com/clinical-trials/NCT02987829)

Status: COMPLETED · Phase: PHASE1/PHASE2 · NCT02987829 · Birmingham, Alabama and 4 others · Sponsor: Tracon Pharmaceuticals Inc.

This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will…

### [This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.](https://www.clareohealth.com/clinical-trials/NCT07028853)

Status: RECRUITING · Phase: PHASE3 · NCT07028853 · Huntsville, Alabama and 318 others · Sponsor: Pfizer

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participan…

### [Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy](https://www.clareohealth.com/clinical-trials/NCT00450411)

Status: COMPLETED · Phase: PHASE2 · NCT00450411 · Phoenix, Arizona and 16 others · Sponsor: Radiation Therapy Oncology Group

RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells.

### [Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer](https://www.clareohealth.com/clinical-trials/NCT03274687)

Status: COMPLETED · Phase: PHASE3 · NCT03274687 · Birmingham, Alabama and 240 others · Sponsor: NRG Oncology

This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostat…

### [BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy](https://www.clareohealth.com/clinical-trials/NCT00016393)

Status: COMPLETED · Phase: PHASE2 · NCT00016393 · Los Angeles, California and 27 others · Sponsor: SWOG Cancer Research Network

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

### [Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer](https://www.clareohealth.com/clinical-trials/NCT02643667)

Status: COMPLETED · Phase: PHASE2 · NCT02643667 · San Francisco, California and 1 other · Sponsor: Washington University School of Medicine

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease.

### [Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations](https://www.clareohealth.com/clinical-trials/NCT05807126)

Status: WITHDRAWN · Phase: PHASE1 · NCT05807126 · Costa Mesa, California and 4 others · Sponsor: National Cancer Institute (NCI)

This phase I/Ib trial studies the side effects and best dose of Hu5F9-G4 (magrolimab) when given in combination with olaparib for the treatment of patients with breast or castrate-…

### [Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing](https://www.clareohealth.com/clinical-trials/NCT03511235)

Status: COMPLETED · NCT03511235 · Little Rock, Arkansas and 7 others · Sponsor: Myriad Genetic Laboratories, Inc.

Medicare is requesting outcome data on patients who received Prolaris testing and were prescribed active surveillance (AS).

### [3-AP in Treating Patients With Advanced Prostate Cancer](https://www.clareohealth.com/clinical-trials/NCT00054015)

Status: COMPLETED · Phase: PHASE2 · NCT00054015 · San Francisco, California and 1 other · Sponsor: Vion Pharmaceuticals

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

### [A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.](https://www.clareohealth.com/clinical-trials/NCT00179738)

Status: TERMINATED · Phase: PHASE2 · NCT00179738 · Berkeley, California and 5 others · Sponsor: Celgene Corporation

Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression

### [Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery](https://www.clareohealth.com/clinical-trials/NCT03541850)

Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · NCT03541850 · Los Angeles, California and 1 other · Sponsor: Jonsson Comprehensive Cancer Center

This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have und…

### [A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide](https://www.clareohealth.com/clinical-trials/NCT05526248)

Status: COMPLETED · Phase: PHASE2 · NCT05526248 · Sherman Oaks, California and 4 others · Sponsor: Bayer

Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer.

### [Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer](https://www.clareohealth.com/clinical-trials/NCT00638378)

Status: TERMINATED · Phase: PHASE2 · NCT00638378 · Highland, California and 14 others · Sponsor: Incyte Corporation

This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androge…

## Prostate Cancer Trials in Other Cities

- [New York](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/new-york)
- [Los Angeles](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/los-angeles)
- [Chicago](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/chicago)
- [Houston](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/houston)
- [Phoenix](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/phoenix)
- [Philadelphia](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/philadelphia)

## Other Conditions in California

- [Breast Cancer](https://www.clareohealth.com/clinical-trials/condition/breast-cancer/california)
- [Lung Cancer](https://www.clareohealth.com/clinical-trials/condition/lung-cancer/california)
- [Colorectal Cancer](https://www.clareohealth.com/clinical-trials/condition/colorectal-cancer/california)
- [Melanoma](https://www.clareohealth.com/clinical-trials/condition/melanoma/california)
- [Leukemia](https://www.clareohealth.com/clinical-trials/condition/leukemia/california)
- [Lymphoma](https://www.clareohealth.com/clinical-trials/condition/lymphoma/california)

Data from [ClinicalTrials.gov](https://clinicaltrials.gov).

---

## Sitemap

This is the Markdown version of https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/california.

- [Home](https://www.clareohealth.com/index.md)
- [About](https://www.clareohealth.com/about.md)
- [Pricing](https://www.clareohealth.com/pricing.md)
- [For providers](https://www.clareohealth.com/providers.md)
- [FAQ](https://www.clareohealth.com/faq.md)
- [Blog](https://www.clareohealth.com/blog.md)
- [Clinical trials](https://www.clareohealth.com/clinical-trials.md)
- [Developers](https://www.clareohealth.com/developers.md)
- [Privacy policy](https://www.clareohealth.com/legal/privacy-policy.md)
- [Terms of service](https://www.clareohealth.com/legal/terms-of-service.md)
- [Every page](https://www.clareohealth.com/sitemap.md)
- [About this site, for agents](https://www.clareohealth.com/llms.txt)
